Eli Lilly unexpectedly lowered its full-year 2024 guidance. The miss appears to stem from a lack of the typical December ...

Eli Lilly shares dropped after the drugmaker cut its 2024 revenue guidance, citing lower-than-expected demand for its obesity ...

Eli Lilly (LLY) revised its revenue outlook on Tuesday for the fourth quarter of 2024 on weaker-than-expected demand for its ...

The shares of Danish weight-loss drug maker Novo Nordisk (NVO) are retreating 5% today, while Eli Lilly (LLY), which makes a similar treatment, is giving back 2.5%. Medicare Selected Novo’s ...

S&P 500 edges higher, Nasdaq dips in choppy session as inflation data eyed 12:08 AM UTC Eli Lilly's stock tumbled 8% on Tuesday after it forecast fourth-quarter sales of weight-loss drug Zepbound ...

New drugs from public and private companies are expected to saturate the obesity drug market. Novo Nordisk and Eli Lilly are currently dominating the weight loss drug market, but biopharmaceutical ...

Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA ... provided a 47% greater relative weight loss compared to Wegovy® (semaglutide).

New data from Novo Nordisk’s phase 3 trial of an oral, high-dose formulation of semaglutide reinforces its potential as a weight-loss therapy in obesity, but Eli ... with Lilly’s drug was ...

The FDA has said it has agreed to reconsider its decision to prevent compounding pharmacies from producing and selling versions of Eli ... weight-loss drugs, with Novo Nordisk and Lilly both ...

Yahoo Finance senior health reporter Anjalee Khemlani explains Novo Nordisk's presence in the US, especially as a GLP-1 weight-loss drug manufacturer, and what US companies like Eli Lilly (LLY) could ...

The weight loss drug Mounjaro costs $1,069 per month if you pay full price or $321 per month if you have insurance coverage. You could pay about $171 per month for Mounjaro if you use a discount from ...